200 related articles for article (PubMed ID: 16421416)
1. Assessing BRCA carrier probabilities in extended families.
Barcenas CH; Hosain GM; Arun B; Zong J; Zhou X; Chen J; Cortada JM; Mills GB; Tomlinson GE; Miller AR; Strong LC; Amos CI
J Clin Oncol; 2006 Jan; 24(3):354-60. PubMed ID: 16421416
[TBL] [Abstract][Full Text] [Related]
2. BRCA1 and BRCA2 mutation predictions using the BOADICEA and BRCAPRO models and penetrance estimation in high-risk French-Canadian families.
Antoniou AC; Durocher F; Smith P; Simard J; Easton DF;
Breast Cancer Res; 2006; 8(1):R3. PubMed ID: 16417652
[TBL] [Abstract][Full Text] [Related]
3. Evaluating the performance of models for predicting the BRCA germline mutations in Han Chinese familial breast cancer patients.
Rao NY; Hu Z; Yu JM; Li WF; Zhang B; Su FX; Wu J; Shen ZZ; Huang W; Shao ZM
Breast Cancer Res Treat; 2009 Aug; 116(3):563-70. PubMed ID: 18807178
[TBL] [Abstract][Full Text] [Related]
4. Application of BRCA1 and BRCA2 mutation carrier prediction models in breast and/or ovarian cancer families of French Canadian descent.
Oros KK; Ghadirian P; Maugard CM; Perret C; Paredes Y; Mes-Masson AM; Foulkes WD; Provencher D; Tonin PN
Clin Genet; 2006 Oct; 70(4):320-9. PubMed ID: 16965326
[TBL] [Abstract][Full Text] [Related]
5. Validation of the pedigree assessment tool (PAT) in families with BRCA1 and BRCA2 mutations.
Teller P; Hoskins KF; Zwaagstra A; Stanislaw C; Iyengar R; Green VL; Gabram SG
Ann Surg Oncol; 2010 Jan; 17(1):240-6. PubMed ID: 19763692
[TBL] [Abstract][Full Text] [Related]
6. Optimal selection of individuals for BRCA mutation testing: a comparison of available methods.
James PA; Doherty R; Harris M; Mukesh BN; Milner A; Young MA; Scott C
J Clin Oncol; 2006 Feb; 24(4):707-15. PubMed ID: 16446345
[TBL] [Abstract][Full Text] [Related]
7. Performance of BRCA1/2 mutation prediction models in male breast cancer patients.
Moghadasi S; Grundeken V; Janssen LAM; Dijkstra NH; Rodríguez-Girondo M; van Zelst-Stams WAG; Oosterwijk JC; Ausems MGEM; Oldenburg RA; Adank MA; Blom EW; Ruijs MWG; van Os TAM; van Deurzen CHM; Martens JWM; Schroder CP; Wijnen JT; Vreeswijk MPG; van Asperen CJ
Clin Genet; 2018 Jan; 93(1):52-59. PubMed ID: 28589637
[TBL] [Abstract][Full Text] [Related]
8. BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes.
Berry DA; Iversen ES; Gudbjartsson DF; Hiller EH; Garber JE; Peshkin BN; Lerman C; Watson P; Lynch HT; Hilsenbeck SG; Rubinstein WS; Hughes KS; Parmigiani G
J Clin Oncol; 2002 Jun; 20(11):2701-12. PubMed ID: 12039933
[TBL] [Abstract][Full Text] [Related]
9. Evaluating the performance of the breast cancer genetic risk models BOADICEA, IBIS, BRCAPRO and Claus for predicting BRCA1/2 mutation carrier probabilities: a study based on 7352 families from the German Hereditary Breast and Ovarian Cancer Consortium.
Fischer C; Kuchenbäcker K; Engel C; Zachariae S; Rhiem K; Meindl A; Rahner N; Dikow N; Plendl H; Debatin I; Grimm T; Gadzicki D; Flöttmann R; Horvath J; Schröck E; Stock F; Schäfer D; Schwaab I; Kartsonaki C; Mavaddat N; Schlegelberger B; Antoniou AC; Schmutzler R;
J Med Genet; 2013 Jun; 50(6):360-7. PubMed ID: 23564750
[TBL] [Abstract][Full Text] [Related]
10. Predicting the likelihood of carrying a BRCA1 or BRCA2 mutation: validation of BOADICEA, BRCAPRO, IBIS, Myriad and the Manchester scoring system using data from UK genetics clinics.
Antoniou AC; Hardy R; Walker L; Evans DG; Shenton A; Eeles R; Shanley S; Pichert G; Izatt L; Rose S; Douglas F; Eccles D; Morrison PJ; Scott J; Zimmern RL; Easton DF; Pharoah PD
J Med Genet; 2008 Jul; 45(7):425-31. PubMed ID: 18413374
[TBL] [Abstract][Full Text] [Related]
11. Improving the accuracy of BRCA1/2 mutation prediction: validation of the novel country-customized IC software.
Capalbo C; Ricevuto E; Vestri A; Sidoni T; Buffone A; Cortesi E; Marchetti P; Scambia G; Tomao S; Rinaldi C; Zani M; Ferraro S; Frati L; Screpanti I; Gulino A; Giannini G
Eur J Hum Genet; 2006 Jan; 14(1):49-54. PubMed ID: 16288312
[TBL] [Abstract][Full Text] [Related]
12. BRCA1 and BRCA2 genetic testing in Hispanic patients: mutation prevalence and evaluation of the BRCAPRO risk assessment model.
Vogel KJ; Atchley DP; Erlichman J; Broglio KR; Ready KJ; Valero V; Amos CI; Hortobagyi GN; Lu KH; Arun B
J Clin Oncol; 2007 Oct; 25(29):4635-41. PubMed ID: 17925560
[TBL] [Abstract][Full Text] [Related]
13. Selecting a BRCA risk assessment model for use in a familial cancer clinic.
Panchal SM; Ennis M; Canon S; Bordeleau LJ
BMC Med Genet; 2008 Dec; 9():116. PubMed ID: 19102775
[TBL] [Abstract][Full Text] [Related]
14. Performance of BOADICEA and BRCAPRO genetic models and of empirical criteria based on cancer family history for predicting BRCA mutation carrier probabilities: a retrospective study in a sample of Italian cancer genetics clinics.
Varesco L; Viassolo V; Viel A; Gismondi V; Radice P; Montagna M; Alducci E; Della Puppa L; Oliani C; Tommasi S; Caligo MA; Vivanet C; Zuradelli M; Mandich P; Tibiletti MG; Cavalli P; Lucci Cordisco E; Turchetti D; Boggiani D; Bracci R; Bruzzi P; Bonelli L
Breast; 2013 Dec; 22(6):1130-5. PubMed ID: 24011770
[TBL] [Abstract][Full Text] [Related]
15. Evaluating BRCA mutation risk predictive models in a Chinese cohort in Taiwan.
Hung FH; Wang YA; Jian JW; Peng HP; Hsieh LL; Hung CF; Yang MM; Yang AS
Sci Rep; 2019 Jul; 9(1):10229. PubMed ID: 31308460
[TBL] [Abstract][Full Text] [Related]
16. Segregation analysis of 231 Ashkenazi Jewish families for evidence of additional breast cancer susceptibility genes.
Kaufman DJ; Beaty TH; Struewing JP
Cancer Epidemiol Biomarkers Prev; 2003 Oct; 12(10):1045-52. PubMed ID: 14578141
[TBL] [Abstract][Full Text] [Related]
17. Optimal selection for BRCA1 and BRCA2 mutation testing using a combination of 'easy to apply' probability models.
Bodmer D; Ligtenberg MJ; van der Hout AH; Gloudemans S; Ansink K; Oosterwijk JC; Hoogerbrugge N
Br J Cancer; 2006 Sep; 95(6):757-62. PubMed ID: 16909138
[TBL] [Abstract][Full Text] [Related]
18. Pretest prediction of BRCA1 or BRCA2 mutation by risk counselors and the computer model BRCAPRO.
Euhus DM; Smith KC; Robinson L; Stucky A; Olopade OI; Cummings S; Garber JE; Chittenden A; Mills GB; Rieger P; Esserman L; Crawford B; Hughes KS; Roche CA; Ganz PA; Seldon J; Fabian CJ; Klemp J; Tomlinson G
J Natl Cancer Inst; 2002 Jun; 94(11):844-51. PubMed ID: 12048272
[TBL] [Abstract][Full Text] [Related]
19. Validation of a tool for identifying women at high risk for hereditary breast cancer in population-based screening.
Hoskins KF; Zwaagstra A; Ranz M
Cancer; 2006 Oct; 107(8):1769-76. PubMed ID: 16967460
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of mathematical models for breast cancer risk assessment in routine clinical use.
Fasching PA; Bani MR; Nestle-Krämling C; Goecke TO; Niederacher D; Beckmann MW; Lux MP
Eur J Cancer Prev; 2007 Jun; 16(3):216-24. PubMed ID: 17415092
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
